Effect of polymorphism on IL1A to cancer susceptibility: Evidence based on 34,016 subjects

Figures & data

Figure 1. Flowchart of the enrolled studies selection procedure.

Table 1. Characteristics of the enrolled studies on IL-1A polymorphism and cancer.

SNP	First author	Year	Ethnicity	Genotyping Method	Source of Control	Cancer Type	Cases			Controls
							1/1	1/2	2/2	1/1	1/2	2/2	HWE
rs17561	Bushley et al.	2004	Mixed	PCR	HB	Ovarian Cancer	146	30	6	151	61	7	Y
rs17561	Ai et al.	2014	Asian	PCR-RFLP	PB	Glioma	118	34	2	169	25	1	Y
rs17561	Zidi et al.	2015	Africa	PCR-RFLP	HB	Cervical Cancer	12	46	30	50	124	86	Y
rs17561	Sousa et al.	2016	Caucasian	TaqMan	HB	Nasopharyngeal Cancer	73	39	10	369	279	55	Y
rs17561	Eaton et al.	2018	Caucasian	Taqman	PB	Lung cancer	303	272	41	316	249	51	Y
rs1800587	Foster et al.	2000	Mixed	PCR	HB	Kaposi Sarcoma	52	47	12	67	45	11	Y
rs1800587	Grimm et al.	2004	Caucasian	PCR	HB	Vulvar Carcinoma	27	31	10	101	114	13	N
rs1800587	Bushley et al.	2004	Mixed	PCR	HB	Ovarian Cancer	140	32	6	150	59	7	Y
rs1800587	Wang et al.	2005	Asian	PCR	HB	Cervical Cancer	18	22	10	27	20	3	Y
rs1800587	Wang et al.	2005	Asian	PCR	PB	Cervical Cancer	27	15	8	23	24	3	Y
rs1800587	Hefler et al.	2005	Caucasian	PCR	PB	Breast Cancer	123	124	22	102	112	13	N
rs1800587	Snoussi et al.	2005	Caucasian	PCR-RFLP	PB	Breast Cancer	116	132	57	83	82	35	Y
rs1800587	Rothman et al.	2006	Mixed	PCR	PB	Lymphoma	1494	1306	253	1740	1436	281	Y
rs1800587	Abazis-Stamboulieh et al.	2007	Caucasian	PCR-RFLP	PB	Multiple Myeloma	27	38	9	116	20	24	N
rs1800587	Braicu et al.	2007	Caucasian	PCR	HB	Ovarian Cancer	65	68	14	65	55	9	Y
rs1800587	Hou et al.	2007	Caucasian	PCR	PB	Gastric Cancer	143	119	43	184	174	59	Y
rs1800587	Ennas et al.	2008	Caucasian	TaqMan	PB	Chronic Lymphocytic Leukaemia	21	15	4	61	42	8	Y
rs1800587	Sáenz-López et al.	2008	Caucasian	PCR	PB	Prostate Cancer	133	135	28	152	122	29	Y
rs1800587	Hoeft et al.	2008	Caucasian	PCR-RFLP	PB	Lymphoma	330	274	46	335	274	50	Y
rs1800587	Sengüven et al.	2011	Caucasian	PCR-RFLP	HB	Odontogenic Tumor	44	20	10	16	10	4	Y
rs1800587	Yang et al.	2011	Asian	PCR-RFLP	PB	Nasopharyngeal Cancer	121	101	26	157	121	18	Y
rs1800587	Eshghyar et al.	2012	Asian	PCR-SSP	PB	Odontogenic Tumor	6	21	3	38	85	22	N
rs1800587	Bai et al.	2013	Asian	TaqMan	HB	Lung cancer	4	26	163	4	33	173	Y
rs1800587	Zheng et al.	2013	Asian	PCR	HB	Esophageal cancer	310	54	2	298	67	5	Y
rs1800587	Ai et al. et al.	2014	Asian	PCR-RFLP	PB	Glioma	114	39	1	151	44	0	Y
rs1800587	Qu et al.	2014	Asian	TaqMan	HB	Nasopharyngeal Cancer	130	29	24	182	46	3	Y
rs1800587	Eaton et al.	2018	Caucasian	Taqman	PB	Lung cancer	299	269	44	312	249	51	Y
rs3783553	Gao et al.	2009	Asian	PCR	PB	HCC	149	676	652	231	815	627	Y
rs3783553	He et al.	2010	Asian	PCR	PB	HCC	22	190	191	58	218	158	Y
rs3783553	Yang et al.	2012	Asian	PCR-RFLP	PB	Nasopharyngeal Cancer	28	106	114	56	132	108	Y
rs3783553	Si et al.	2013	Asian	PCR	PB	Glioma	12	72	77	29	99	78	Y
rs3783553	Liao et al.	2014	Asian	PCR-PAGE	PB	Prostate Cancer	8	53	70	30	118	81	Y
rs3783553	Zeng et al.	2014	Asian	PCR	PB	Gastric Cancer	15	102	90	51	183	147	Y
rs3783553	Gao et al.	2014	Asian	PCR	PB	Thyroid Carcinoma	29	132	112	56	242	211	Y
rs3783553	Zhang et al.	2014	Asian	PCR	PB	Ovarian Cancer	29	126	146	36	110	94	Y
rs3783553	Pu et al.	2014	Asian	PCR	PB	Cervical Cancer	26	140	153	60	201	163	Y
rs3783553	Du et al.	2014	Asian	PCR	PB	HCC	113	451	434	111	463	431	Y
rs3783553	Huang et al.	2015	Asian	PCR	PB	Cervical Cancer	13	134	88	33	147	134	Y
rs3783553	Zhang et al.	2015	Caucasion	PCR	PB	Oral Squamous Cell Carcinoma	35	144	146	60	163	112	Y
rs3783553	Yan et al.	2015	Asian	PCR	PB	Colorectal Cancer	37	160	142	46	143	124	Y
rs3783553	Huang et al.	2016	Asian	PCR	PB	Breast Cancer	24	113	91	45	115	81	Y
rs3783553	Yu et al.	2016	Asian	PCR-PAGE	PB	Endometrial Cancer	26	127	119	45	132	117	Y
rs3783553	Zhang et al.	2016	Asian	PCR	PB	Gastric Cancer	46	244	229	80	258	198	Y
rs3783553	Hashemi et al.	2017	Caucasion	PCR-RFLP	HB	Prostate Cancer	63	71	16	83	65	7	Y
rs3783553	Ma et al.	2018	Asian	PCR	PB	Colorectal Cancer	28	176	178	70	200	163	Y

1/1: wild homozygote; 1/2: heterozygote; 2/2: mutant homozygote.

Table 2. Results of pooled analysis for IL-1A polymorphism and cancer susceptibility.

SNP	Comparison	Subgroup	N	PH	PZ	Random	Fixed
rs17561	G vs. T	Overall	5	0.013	0.995	0.999 (0.771–1.295)	0.987 (0.869–1.121)
rs17561	G/G vs. T/T	Overall	5	0.673	0.855	0.967 (0.703–1.33)	0.971 (0.708–1.331)
rs17561	G/T vs. T/T	Overall	5	0.001	0.955	1.012 (0.664–1.542)	1.013 (0.854–1.201)
rs17561	G/G + G/T vs. T/T	Overall	5	0.002	0.923	1.019 (0.693–1.499)	1 (0.849–1.177)
rs17561	G/G vs. G/T + T/T	Overall	5	0.81	0.647	0.935 (0.703–1.243)	0.935 (0.703–1.244)
rs17561	G vs. T	Caucasian	2	0.292	0.655	0.962 (0.814–1.137)	0.966 (0.829–1.125)
rs17561	G/G vs. T/T	Caucasian	2	0.831	0.432	0.86 (0.591–1.251)	0.86 (0.59–1.253)
rs17561	G/T vs. T/T	Caucasian	2	0.051	0.75	0.927 (0.583–1.474)	1.015 (0.829–1.242)
rs17561	G/G + T/T vs. T/T	Caucasian	2	0.095	0.701	0.93 (0.643–1.346)	0.989 (0.815–1.2)
rs17561	G/G vs. G/T + T/T	Caucasian	2	0.495	0.395	0.853 (0.592–1.229)	0.853 (0.59–1.231)
rs17561	G vs. T	PB	2	0.025	0.373	1.317 (0.719–2.413)	1.08 (0.915–1.274)
rs17561	G/G vs. T/T	PB	2	0.326	0.546	0.872 (0.566–1.345)	0.876 (0.569–1.348)
rs17561	G/T vs. T/T	PB	2	0.087	0.2	1.396 (0.838–2.325)	1.232 (0.993–1.527)
rs17561	G/G + G/T vs. T/T	PB	2	0.05	0.266	1.388 (0.779–2.474)	1.183 (0.962–1.455)
rs17561	G/G vs. G/T + T/T	PB	2	0.347	0.358	0.819 (0.538–1.247)	0.822 (0.54–1.249)
rs17561	G vs. T	HB	3	0.088	0.338	0.855 (0.621–1.177)	0.865 (0.707–1.057)
rs17561	G/G vs. T/T	HB	3	0.635	0.701	1.092 (0.681–1.75)	1.095 (0.689–1.739)
rs17561	G/T vs. T/T	HB	3	0.043	0.357	0.775 (0.451–1.333)	0.722 (0.542–0.96)
rs17561	G/G + G/T vs. T/T	HB	3	0.055	0.373	0.8 (0.49–1.306)	0.754 (0.576-0.986)
rs17561	G/G vs. G/T + T/T	HB	3	1	0.818	1.046 (0.71–1.541)	1.046 (0.71–1.541)
rs1800587	C vs. T	Overall	22	0.002	0.018	1.119 (1.019–1.228)	1.069 (1.016–1.124)
rs1800587	C/C vs. T/T	Overall	22	0.05	0.021	1.259 (1.035–1.53)	1.16 (1.028–1.309)
rs1800587	C/T vs. T/T	Overall	22	<0.001	0.294	1.077 (0.937–1.238)	1.061 (0.991–1.136)
rs1800587	C/C + C/T vs. T/T	Overall	22	0.002	0.075	1.117 (0.989–1.261)	1.078 (1.01–1.15)
rs1800587	C/C vs. C/T + T/T	Overall	22	0.032	0.06	1.195 (0.992–1.439)	1.116 (0.996–1.25)
rs1800587	C vs. T	Asians	8	0.008	0.104	1.234 (0.958–1.59)	1.221 (1.057–1.411)
rs1800587	C/C vs. T/T	Asians	8	0.027	0.054	2.04 (0.989–4.209)	2.293 (1.546–3.401)
rs1800587	C/T vs. T/T	Asians	8	0.459	0.805	0.975 (0.803–1.184)	0.976 (0.805–1.184)
rs1800587	C/C + C/T vs. T/T	Asians	8	0.19	0.231	1.135 (0.894–1.44)	1.118 (0.931–1.343)
rs1800587	C/C vs. C/T + T/T	Asians	8	0.007	0.056	1.898 (0.985–3.658)	1.8 (1.319–2.457)
rs1800587	C vs. T	Caucasian	11	0.08	0.084	1.103 (0.987–1.233)	1.072 (0.99–1.161)
rs1800587	C/C vs. T/T	Caucasian	11	0.626	0.325	1.101 (0.916–1.324)	1.097 (0.912–1.318)
rs1800587	C/T vs. T/T	Caucasian	11	<0.001	0.143	1.193 (0.942–1.512)	1.117 (1.001–1.246)
rs1800587	C/C + C/T vs. T/T	Caucasian	11	0.002	0.102	1.172 (0.969–1.419)	1.11 (1.001–1.232)
rs1800587	C/C vs. C/T + T/T	Caucasian	11	0.587	0.66	1.045 (0.876–1.245)	1.04 (0.873–1.239)
rs1800587	C vs. T	PB	13	0.178	0.049	1.075 (0.995–1.162)	1.056 (1–1.115)
rs1800587	C/C vs. T/T	PB	13	0.806	0.246	1.078 (0.947–1.228)	1.079 (0.949–1.228)
rs1800587	C/T vs. T/T	PB	13	<0.001	0.12	1.149 (0.965–1.369)	1.084 (1.008–1.167)
rs1800587	C/C + C/T vs. T/T	PB	13	0.005	0.076	1.135 (0.987–1.305)	1.083 (1.01–1.162)
rs1800587	C/C vs. C/T + T/T	PB	13	0.672	0.58	1.034 (0.913–1.171)	1.036 (0.915–1.172)
rs1800587	C vs. T	HB	9	0.001	0.227	1.176 (0.904–1.529)	1.16 (1.009–1.334)
rs1800587	C/C vs. T/T	HB	9	0.016	0.065	1.748 (0.966–3.162)	1.957 (1.375–2.785)
rs1800587	C/T vs. T/T	HB	9	0.294	0.388	0.931 (0.752–1.153)	0.92 (0.762–1.111)
rs1800587	C/C + C/T vs. T/T	HB	9	0.044	0.578	1.078 (0.827–1.407)	1.045 (0.876–1.247)
rs1800587	C/C vs. C/T + T/T	HB	9	0.013	0.046	1.69 (1.01–2.827)	1.687 (1.258–2.263)
rs1800587	C vs. T	Breast Cancer	2	0.758	0.465	1.072 (0.889–1.293)	1.072 (0.889–1.293)
rs1800587	C/C vs. T/T	Breast Cancer	2	0.683	0.315	1.237 (0.815–1.877)	1.238 (0.816–1.878)
rs1800587	C/T vs. T/T	Breast Cancer	2	0.409	0.886	1.02 (0.78–1.334)	1.02 (0.78–1.333)
rs1800587	C/C + C/T vs. T/T	Breast Cancer	2	0.496	0.677	1.056 (0.819–1.361)	1.056 (0.819–1.361)
rs1800587	C/C vs. C/T + T/T	Breast Cancer	2	0.485	0.384	1.186 (0.804–1.75)	1.188 (0.806–1.752)
rs1800587	C vs. T	Cervical Cancer	2	0.118	0.07	1.471 (0.759–2.854)	1.475 (0.968–2.247)
rs1800587	C/C vs. T/T	Cervical Cancer	2	0.445	0.017	3.386 (1.232–9.308)	3.396 (1.242–9.285)
rs1800587	C/T vs. T/T	Cervical Cancer	2	0.065	0.909	0.938 (0.309–2.841)	0.937 (0.52–1.69)
rs1800587	C/C + C/T vs. T/T	Cervical Cancer	2	0.065	0.699	1.227 (0.436–3.455)	1.219 (0.702–2.116)
rs1800587	C/C vs. C/T + T/T	Cervical Cancer	2	0.784	0.013	3.43 (1.299–9.06)	3.439 (1.304-9.072)
rs1800587	C vs. T	Lung cancer	2	0.73	0.681	1.035 (0.878–1.22)	1.035 (0.878–1.22)
rs1800587	C/C vs. T/T	Lung cancer	2	0.952	0.632	0.904 (0.597–1.367)	0.904 (0.597–1.367)
rs1800587	C/T vs. T/T	Lung cancer	2	0.639	0.347	1.117 (0.887–1.408)	1.117 (0.887–1.408)
rs1800587	C/C + C/T vs. T/T	Lung cancer	2	0.813	0.475	1.084 (0.869–1.353)	1.084 (0.869–1.353)
rs1800587	C/C vs. C/T + T/T	Lung cancer	2	0.367	0.813	0.961 (0.692–1.335)	0.961 (0.693–1.334)
rs1800587	C vs. T	Lymphoma	2	0.609	0.402	1.03 (0.961–1.104)	1.03 (0.961–1.104)
rs1800587	C/C vs. T/T	Lymphoma	2	0.626	0.732	1.03 (0.87–1.219)	1.03 (0.87–1.219)
rs1800587	C/T vs. T/T	Lymphoma	2	0.737	0.288	1.052 (0.958–1.154)	1.052 (0.958–1.154)
rs1800587	C/C + C/T vs. T/T	Lymphoma	2	0.66	0.3	1.048 (0.959–1.145)	1.048 (0.959–1.145)
rs1800587	C/C vs. C/T + T/T	Lymphoma	2	0.677	0.94	1.006 (0.855–1.185)	1.006 (0.855–1.185)
rs1800587	C vs. T	Odontogenic Tumor	2	0.705	0.825	0.952 (0.622–1.459)	0.953 (0.621–1.461)
rs1800587	C/C vs. T/T	Odontogenic Tumor	2	0.959	0.812	0.889 (0.336–2.356)	0.889 (0.336–2.351)
rs1800587	C/T vs. T/T	Odontogenic Tumor	2	0.272	0.842	1.055 (0.498–2.236)	1.071 (0.547–2.096)
rs1800587	C/C + C/T vs. T/T	Odontogenic Tumor	2	0.362	0.94	1.014 (0.534–1.923)	1.025 (0.546–1.923)
rs1800587	C/C vs. C/T + T/T	Odontogenic Tumor	2	0.588	0.588	0.799 (0.328–1.949)	0.787 (0.331–1.873)
rs1800587	C vs. T	Ovarian Cancer	2	0.039	0.798	0.929 (0.531–1.628)	0.948 (0.725–1.239)
rs1800587	C/C vs. T/T	Ovarian Cancer	2	0.472	0.511	1.262 (0.625–2.547)	1.264 (0.629–2.537)
rs1800587	C/T vs. T/T	Ovarian Cancer	2	0.033	0.659	0.847 (0.404–1.774)	0.84 (0.596–1.183)
rs1800587	C/C + C/T vs. T/T	Ovarian Cancer	2	0.03	0.743	0.887 (0.433–1.816)	0.877 (0.632–1.216)
rs1800587	C/C vs. C/T + T/T	Ovarian Cancer	2	0.679	0.516	1.252 (0.631–2.486)	1.254 (0.633–2.482)
rs1800587	C vs. T	Y	18	0.02	0.091	1.082 (0.988–1.186)	1.055 (1.001–1.111)
rs1800587	C/C vs. T/T	Y	18	0.05	0.084	1.206 (0.975–1.49)	1.131 (0.998–1.282)
rs1800587	C/T vs. T/T	Y	18	0.453	0.279	1.04 (0.969–1.117)	1.04 (0.969–1.116)
rs1800587	C/C + C/T vs. T/T	Y	18	0.279	0.107	1.059 (0.97–1.155)	1.057 (0.988–1.131)
rs1800587	C/C vs. C/T + T/T	Y	18	0.047	0.109	1.173 (0.965–1.426)	1.105 (0.982–1.244)
rs1800587	C vs. T	N	4	0.021	0.113	1.338 (0.934–1.918)	1.27 (1.054–1.531)
rs1800587	C/C vs. T/T	N	4	0.511	0.037	1.657 (1.049–2.617)	1.628 (1.031–2.571)
rs1800587	C/T vs. T/T	N	4	<0.001	0.23	1.827 (0.683–4.887)	1.4 (1.077–1.821)
rs1800587	C/C + C/T vs. T/T	N	4	<0.001	0.183	1.647 (0.791–3.432)	1.413 (1.099–1.817)
rs1800587	C/C vs. C/T + T/T	N	4	0.112	0.275	1.274 (0.681–2.386)	1.263 (0.83–1.92)
rs3783553	Ins vs. Del	Overall	18	0.003	<0.001	1.3 (1.205–1.402)	1.269 (1.209–1.331)
rs3783553	Ins/Ins vs. Del/Del	Overall	18	0.006	<0.001	1.879 (1.582–2.23)	1.752 (1.57–1.954)
rs3783553	Ins/Del vs. Del/Del	Overall	18	0.235	<0.001	1.49 (1.317–1.687)	1.457 (1.31–1.621)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	Overall	18	0.046	<0.001	1.659 (1.443–1.907)	1.585 (1.432–1.754)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	Overall	18	0.014	<0.001	1.308 (1.186–1.443)	1.285 (1.202–1.372)
rs3783553	Ins vs. Del	Asian	16	0.003	<0.001	1.281 (1.183–1.387)	1.254 (1.193–1.318)
rs3783553	Ins/Ins vs. Del/Del	Asian	16	0.005	<0.001	1.835 (1.529–2.202)	1.715 (1.531–1.92)
rs3783553	Ins/Del vs. Del/Del	Asian	16	0.144	<0.001	1.512 (1.312–1.742)	1.455 (1.301–1.628)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	Asian	16	0.025	<0.001	1.666 (1.423–1.949)	1.573 (1.413–1.75)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	Asian	16	0.022	<0.001	1.281 (1.16–1.414)	1.266 (1.183–1.354)
rs3783553	Ins vs. Del	Caucasian	2	0.903	<0.001	1.501 (1.243–1.813)	1.501 (1.243–1.813)
rs3783553	Ins/Ins vs. Del/Del	Caucasian	2	0.582	<0.001	2.377 (1.545–3.658)	2.382 (1.549–3.664)
rs3783553	Ins/Del vs. Del/Del	Caucasian	2	0.881	0.022	1.476 (1.058–2.06)	1.476 (1.058–2.06)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	Caucasian	2	0.696	0.001	1.697 (1.234–2.334)	1.699 (1.236–2.335)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	Caucasian	2	0.373	<0.001	1.701 (1.263–2.292)	1.707 (1.268–2.298)
rs3783553	Ins vs. Del	PB	17	0.003	<0.001	1.293 (1.196–1.397)	1.264 (1.204–1.327)
rs3783553	Ins/Ins vs. Del/Del	PB	17	0.005	<0.001	1.855 (1.559–2.208)	1.738 (1.557–1.941)
rs3783553	Ins/Del vs. Del/Del	PB	17	0.186	<0.001	1.503 (1.317–1.716)	1.458 (1.307–1.626)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	PB	17	0.032	<0.001	1.67 (1.44–1.936)	1.585 (1.428–1.758)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	PB	17	0.017	<0.001	1.298 (1.178–1.43)	1.28 (1.198–1.367)
rs3783553	Ins vs. Del	Cervical Cancer	2	0.039	0.316	1.193 (0.845–1.685)	1.217 (1.032–1.435)
rs3783553	Ins/Ins vs. Del/Del	Cervical Cancer	2	0.552	0.001	1.977 (1.31–2.983)	1.976 (1.309–2.982)
rs3783553	Ins/Del vs. Del/Del	Cervical Cancer	2	0.402	0.003	1.83 (1.217–2.752)	1.836 (1.222–2.758)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	Cervical Cancer	2	0.855	0.001	1.908 (1.289–2.823)	1.908 (1.289–2.824)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	Cervical Cancer	2	0.009	0.76	1.097 (0.605–1.989)	1.142 (0.914–1.428)
rs3783553	Ins vs. Del	Colorectal Cancer	2	0.093	0.042	1.306 (1.01–1.688)	1.317 (1.131–1.533)
rs3783553	Ins/Ins vs. Del/Del	Colorectal Cancer	2	0.066	0.037	1.975 (1.043–3.739)	2.001 (1.419–2.821)
rs3783553	Ins/Del vs. Del/Del	Colorectal Cancer	2	0.19	0.001	1.752 (1.118–2.746)	1.766 (1.256–2.483)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	Colorectal Cancer	2	0.099	0.025	1.852 (1.08–3.177)	1.872 (1.354–2.588)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	Colorectal Cancer	2	0.2	0.02	1.272 (0.973–1.663)	1.279 (1.039–1.576)
rs3783553	Ins vs. Del	Gastric Cancer	2	0.776	<0.001	1.315 (1.137–1.522)	1.315 (1.137–1.522)
rs3783553	Ins/Ins vs. Del/Del	Gastric Cancer	2	0.929	<0.001	2.032 (1.441–2.866)	2.033 (1.441–2.867)
rs3783553	Ins/Del vs. Del/Del	Gastric Cancer	2	0.709	0.002	1.715 (1.222–2.405)	1.718 (1.225–2.409)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	Gastric Cancer	2	0.8	<0.001	1.853 (1.34–2.563)	1.856 (1.342–2.566)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	Gastric Cancer	2	0.656	0.009	1.305 (1.068–1.594)	1.305 (1.068–1.594)
rs3783553	Ins vs. Del	HCC	3	0.002	0.049	1.231 (1.001–1.514)	1.198 (1.111–1.292)
rs3783553	Ins/Ins vs. Del/Del	HCC	3	<0.001	0.067	1.645 (0.966–2.801)	1.474 (1.242–1.749)
rs3783553	Ins/Del vs. Del/Del	HCC	3	0.015	0.145	1.333 (0.906–1.963)	1.243 (1.049–1.473)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	HCC	3	0.002	0.091	1.474 (0.94–2.312)	1.345 (1.144–1.58)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	HCC	3	0.018	0.038	1.265 (1.014–1.578)	1.24 (1.119–1.375)
rs3783553	Ins vs. Del	Prostate Cancer	2	0.539	<0.001	1.655 (1.3–2.106)	1.657 (1.302–2.108)
rs3783553	Ins/Ins vs. Del/Del	Prostate Cancer	2	0.91	<0.001	3.137 (1.672–5.888)	3.142 (1.674–5.896)
rs3783553	Ins/Del vs. Del/Del	Prostate Cancer	2	0.749	0.053	1.494 (0.991–2.251)	1.497 (0.994–2.255)
rs3783553	Ins/Ins + Ins/Del vs. Del/Del	Prostate Cancer	2	0.427	0.005	1.74 (1.172–2.584)	1.758 (1.187–2.604)
rs3783553	Ins/Ins vs. Ins/Del + Del/Del	Prostate Cancer	2	0.72	<0.001	2.17 (1.462–3.22)	2.175 (1.466–3.226)

Figure 2. Meta-analysis of the association between IL1A rs1800587 polymorphism and cancer risk.

Figure 3. Meta-analysis of the association between IL1A rs3783553 polymorphism and cancer risk.

Figure 4. Sensitivity analysis for IL1A rs1800587 polymorphism and cancer risk.

Figure 5. Sensitivity analysis for IL1A rs3783553 polymorphism and cancer risk.

Figure 6. Begg’s funnel plot for IL1A polymorphisms and cancer risk. The x-axis is log (OR), and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate.